CYTOKINE PRODUCTION IN 5 TUMOR-CELL LINES WITH ACTIVITY TO INDUCE CANCER CACHEXIA SYNDROME IN NUDE-MICE

被引：25

作者：

ISEKI, H

KAJIMURA, N

OHUE, C

TANAKA, R

AKIYAMA, Y

YAMAGUCHI, K

机构：

[1] NATL CANC CTR,RES INST,DIV GROWTH FACTOR,CHUO KU,TOKYO 104,JAPAN

[2] TOKYO MED & DENT UNIV,DEPT SURG 2,BUNKYO KU,TOKYO 113,JAPAN

来源：

JAPANESE JOURNAL OF CANCER RESEARCH | 1995年 / 86卷 / 06期

关键词：

CACHEXIA; LIF; IL-6; CYTOKINE; CANCER;

D O I：

10.1111/j.1349-7006.1995.tb02435.x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To identify the so-called toxohormone, which is a tumor-derived factor with activity to induce cancer cachexia syndrome in tumor-bearing animals, 5 human cancer cell lines with this activity were studied for cytokine production. Tumor cell products with activity to inhibit lipoprotein lipase (LPL) were shown to play an important role in the development of the cancer cachexia syndrome. All culture media conditioned by the 5 cell lines possessed LPL-inhibitory activity. However, the activity differed with the cell line. In order to characterize the activity, we examined whether the cultured cells produced cytokines with activity to inhibit LPL. A melanoma cell line, SEKI, and a neuoepithelioma cell Line, NAGAI, were found to express a large amount of leukemia inhibitory factor (LIF) mRNA. Furthermore, both of these cell lines were demonstrated to produce a large amount of LIF protein, and plasma levels of LIF were extremely elevated in SEKI- and NAGAI-bearing nude mice, indicating that LIF produced by the tumor cells induced cancer cachexia syndrome in the animals. Thus, LIF fulfills the requirements for a toxohormone, except for suppressive activity on liver catalase. In contrast, the mechanisms responsible for cachexia in the MKN-1-, LX-1- and LS180-bearing mice remain unknown. These findings suggest that various types of bioactive substances produced by cancer cells could be toxohormones.

引用

页码：562 / 567

页数：6

共 29 条

[21]

Pennica D., Nedwin G.E., Hayflick J.S., Seeburg P.H., Derynck R., Palladino M.A., Kohr W.J., Aggarwal B.B., Goeddel D.V., Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin, Nature, 312, pp. 724-729, (1984)

[22]

Gray P.W., Goeddel D.V., Structure of the human immune interferon gene, Nature, 298, pp. 859-863, (1982)

[23]

Hirano T., Yasukawa K., Harada H., Taga T., Watanabe Y., Matsuda T., Kashiwamura S., Nakajima K., Koyama K., Iwamatsu A., Tsunasawa S., Sakiyama F., Matsui H., Takahara Y., Taniguchi T., Kishimoto T., Complementary DNA for a novel human interleukin (BSF‐2) that induces B lymphocytes to produce immunoglobulin, Nature, 324, pp. 73-76, (1986)

[24]

Shibata Y., Tamura K., Ishida N., In vivo analysis of the suppressive effects of immunosuppressive acidic protein, a type of α1‐acid glycoprotein, in connection with its high level in tumor‐bearing mice, Cancer Res., 43, pp. 2889-2896, (1983)

[25]

Kawakami M., Murase T., Ogawa H., Ishibashi S., Mori N., Takaku F., Shibata S., Human recombinant TNF suppresses lipoprotein lipase activity and stimulates lipolysis in 3T3‐L1 cells, J. Biochem., 101, pp. 331-338, (1987)

[26]

Beutler B.A., Cerami A., Recombinant interleukin 1 suppresses lipoprotein lipase activity in 3T3‐L1 cells, J. Immunol., 135, pp. 3969-3971, (1985)

[27]

Patton J.S., Shepard H.M., Wilking H., Lewis G., Aggarwal B.B., Eessalu T.E., Gavin L.A., Grunfeld C., Interferons and tumor necrosis factors have similar catabolic effects on 3T3 L1 cells, Proc. Natl. Acad. Sci. USA, 83, pp. 8313-8317, (1986)

[28]

Baumann H., Wong G.G., Hepatocyte‐stimulating factor III shares structural and functional identity with leukemia‐inhibitory factor, J. Immunol., 143, pp. 1163-1167, (1989)

[29]

Marinkovic S., Jahreis G.P., Wong G.G., Baumann H., IL‐6 modulates the synthesis of a specific set of acute phase plasma proteins in vivo, J. Immunol., 142, pp. 808-812, (1989)

← 1 2 3 →